Sivopixant + Placebo + Acetazolamide + SASS-001
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Apnea
Conditions
Sleep Apnea
Trial Timeline
Apr 2, 2025 → Dec 1, 2025
NCT ID
NCT06776432About Sivopixant + Placebo + Acetazolamide + SASS-001
Sivopixant + Placebo + Acetazolamide + SASS-001 is a phase 2 stage product being developed by Shionogi for Sleep Apnea. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06776432. Target conditions include Sleep Apnea.
What happened to similar drugs?
20 of 20 similar drugs in Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06776432 | Phase 2 | Recruiting |
Competing Products
20 competing products in Sleep Apnea